Organoids: A New Chapter in Sarcoma Diagnosis and Treatment

Psilopatis, Iason; Kokkali, Stefania; Palamaris, Kostas; Digklia, Antonia; Vrettou, Kleio; Theocharis, Stamatios

doi:10.3390/ijms231911271

Cited by 11 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, these disadvantages are not limited to only TNBC patient-derived organoids. Similar limitations have been described for other cancer entities as well, thus outlining the imperative need for further research in the field of organoid culture optimization [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 62%

“…Since their initial application, patient-derived organoids have provided great insights into the pathophysiology of numerous cancer entities and, especially, shed light on obscure and otherwise unexplainable aspects related to the pathogenesis of scarce or complex tumors [ 20 , 21 , 22 , 23 ]. TNBC belongs to the multifaceted and, consequently, aggressive subtypes of breast cancer, as it does not abide by the well-understood hormonal pathways that characterize the more common hormone-receptor positive breast cancer entities but develops and spreads through diverse and extremely complicated molecular mechanisms [ 24 ].…”

Section: The Role Of Patient-derived Organoids In the Understanding O...mentioning

confidence: 99%

See 1 more Smart Citation

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening

et al. 2023

Self Cite

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes, with a grave prognosis and few effective treatment options. Organoids represent revolutionary three-dimensional cell culture models, derived from stem or differentiated cells and preserving the capacity to differentiate into the cell types of their tissue of origin. The current review aims at studying the potential of patient-derived TNBC organoids for drug sensitivity testing as well as highlighting the advantages of the organoid technology in terms of drug screening. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The search terms “organoid” and “triple-negative breast cancer” were employed, and we were able to identify 25 studies published between 2018 and 2022. The current manuscript represents the first comprehensive review of the literature focusing on the use of patient-derived organoids for drug sensitivity testing in TNBC. Patient-derived organoids are excellent in vitro study models capable of promoting personalized TNBC therapy by reflecting the treatment responses of the corresponding patients and exhibiting high predictive value in the context of patient survival evaluation.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: The Role Of Patient-derived Organoids In the Understanding O...mentioning

confidence: 99%

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…[20,21] At the time of diagnosis, 10% of STS patients have already developed distant metastases, lost the opportunity for radical surgery, and the 5-year survival rate drops to 15%. [7] Hence, it is vital to explore novel biomarkers that can predict early diagnosis and prognosis in STS patients.…”

Section: Discussionmentioning

confidence: 99%

“…When patients with STS have distant metastases, the 5-year survival rate drops to 15%. [7] Therefore, these…”

Section: Introductionmentioning

confidence: 95%

The expression and clinical significance of UHRF1 in soft tissue sarcomas and its prognostic value

Shu,

Liu,

Xiang

et al. 2024

Medicine

View full text Add to dashboard Cite

To explore the expression and prognostic value of UHRF1 gene in soft tissue sarcoma (STS) and its related molecular mechanism. The expression data and clinicopathological parameters of STS were downloaded from the Cancer Genome Atlas (TCGA). The expression level of UHRF1 in STS and adjacent tissues and its relationship with clinicopathological characteristics were analyzed. The expression level of UHRF1 in STS tissues was significantly higher than that in paracancerous tissues (P < .001), and the overall survival (OS) time of patients with high UHRF1 expression was significantly shorter than that of patients with low UHRF1 expression (P = .002). The expression of UHRF1 was correlated with tumor necrosis, histological type and metastasis, and the differences were statistically significant (P = .013; P = .001; P = .002). The area ratio under receiver operating characteristic (ROC) curve between STS tissue and adjacent tissue of UHRF1 expression was 0.994. Number of tumors (HR = 0.416, 95%CI = 0.260–0.666, P < .001), depth of tumor (HR = 2.888, 95%CI = 0.910–9.168, P = .033), metastasis (HR = 2.888, 95% CI = 1.762–4.732, P < .001), residual tumor (HR = 2.637, 95% CI = 1.721–4.038, P < .001) and UHRF1 expression (HR = 1.342, 95% CI = 1.105–1.630, P = .003) were significantly associated with OS, and high expression of UHRF1 (HR = 1.387, 95%CI = 1.008–1.907, P = .044) was an independent risk factor for the prognosis of STS patients. The results of the nomogram exhibited that UHRF1 expression level had a significant effect on the total score value. GSEA enrichment analysis suggested that UHRF1 was involved in 14 signaling pathways regulating mRNA spliceosome, cell cycle, P53 signaling pathway were identified. Single sample gene set enrichment analysis (ssGSEA) exhibited that the expression of UHRF1 in STS was positively correlated with the level of Th2 cell infiltration, and negatively correlated with plasmacytoid dendritic cells (pDC), natural killer cells (NK), Eosinophils, Mast cells, etc. UHRF1 expression is involved in the immune microenvironment of HCC and affects the occurrence and development of HCC. UHRF1 is highly expressed in STS tissues. It is involved in the regulation of multiple tumor-related signaling pathways and immune cell microenvironment, suggesting that UHRF1 may be a potential molecular marker for prognosis prediction and targeted therapy of STS patients.

show abstract

“…Only two research groups conducted clinical trials and published the most promising results concerning the application of valproic acid (in combination with other treatment agents) in cervical carcinoma patients. Consequently, future studies could incorporate further cervical cancer cell lines but should also take into consideration the advantages of the employment of more reliable, three-dimensional testing models including organoids, which have so far been described as the most useful drug sensitivity screening platforms in different types of (gynecological) cancer [ 139 , 140 , 141 ]. Preferably, the conduction of clinical trials with large patient collectives could help verify the clinical utility and safety of diverse HDACIs in cervical cancer therapy, as well as inspect eventual adverse side effects resulting from their application to women.…”

Section: Discussionmentioning

confidence: 99%

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy

Psilopatis

Garmpis

Garmpi

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Cervical carcinoma is one of the most common cancers among women globally. Histone deacetylase inhibitors (HDACIs) constitute anticancer drugs that, by increasing the histone acetylation level in various cell types, induce differentiation, cell cycle arrest, and apoptosis. The aim of the current review is to study the role of HDACIs in the treatment of cervical cancer. A literature review was conducted using the MEDLINE and LIVIVO databases with a view to identifying relevant studies. By employing the search terms “histone deacetylase” and “cervical cancer”, we managed to identify 95 studies published between 2001 and 2023. The present work embodies the most up-to-date, comprehensive review of the literature centering on the particular role of HDACIs as treatment agents for cervical cancer. Both well-established and novel HDACIs seem to represent modern, efficacious anticancer drugs, which, alone or in combination with other treatments, may successfully inhibit cervical cancer cell growth, induce cell cycle arrest, and provoke apoptosis. In summary, histone deacetylases seem to represent promising future treatment targets in cervical cancer.

show abstract

Organoids: A New Chapter in Sarcoma Diagnosis and Treatment

Cited by 11 publications

References 41 publications

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening

The expression and clinical significance of UHRF1 in soft tissue sarcomas and its prognostic value

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy

Contact Info

Product

Resources

About